MERCK SHARPE & DOHME CASE SUMMARY QUESTIONS 1. Provide brief Background and Context In 1996 Merc Sharp & Dohme (MSD)‚ one of the top tier pharmaceutical firms in Argentina was undergoing fundamental changes in both its organizational structure as well as managerial philosophy. For over a year the company was under a new managing director who was leading the transformation of the company. The main goals at the time were to change the old hierarchical management system into a flatter
Premium Ethics Management
Merck & Co.‚ Inc. Case If one hold a key to resolve a very serious problem‚ one has a responsibility to put an effort to make it happen‚ at least try one’s best. In this case‚ river blindness disease was a very serious problem‚ and Dr. Vagelos was the one who could make a decision as to whether the research and development of a human version of ivermectin should be carried on‚ then it was his responsibility to pursue it. Caused by a parasitic worm carried by a tiny black fly‚ the disease
Premium Blindness Human Onchocerciasis
CASE 5.1: MERCK ACQUISITION OF MEDCO Abstract Corporate mergers and acquisitions (M&A) have become popular across the globe during the last two decades due to globalization‚ liberalization‚ technological developments‚ and competitive business environment (Fisher & Siburg‚ 2009). The synergistic gains from M&A may result from efficient management‚ economies of scale‚ profitable use of assets‚ exploitation of market power‚ and the use of complementary resources (Mitchell
Premium Pharmacology Pharmaceutical industry Pharmacy
decision (not covered in class?) Based on the pyramid of social responsibility‚ Merck is required to be profitable (base). Since the research of development will never be profitable to shareholders Merck should do develop the drug. Based on Merck’s actual value system‚ it wants to be ethical and even be a good corporate citizen. So Merck should conduct the research. Question 8 - If you were the senior executive of Merck‚ what would you do? (Open question) I would make assessment of the potential costs
Premium Social responsibility Corporation Business ethics
1. How has Merck been able to achieve substantial returns to capital given the large costs and lengthy time to develop drugs? Merck had a 14% increase in sales between 1997 and 1998 and 22% increase in sales from 1998 – 1999‚ and a 13% annual increase in earnings over the same period. Merck’s business strategy consists of two parts: (1) developing and marketing new drugs through internal research‚ and (2) developing partnerships with smaller biotechnology companies. Since 1995‚ Merck had launched
Premium Expected value License Money
Pharmaceuticals: Merck Sustaining Long-term Advantage Through Information Technology Hiroshi Amari Working Paper No. 161 Working Paper Series Center on Japanese Economy and Business Columbia Business School December 1998 Columbia-Yale Project: Use of Software to Achieve Competitive Advantage PHARMACEUTICALS: MERCK Sustaining Long-term Advantage Through Information Technology Prepared by Hiroshi Amari Research Associate‚ Yale University William V. Rapp and Hugh T. Patrick Co-principal
Premium Clinical trial Pharmaceutical industry Drug development
Shareholders Report. Merck Co Inc. Merck Co Inc. (hereinafter referred as “Merck”) is US pharmaceutical company which have had created‚ manufactured and made various distribution models of drugs avalaible. One of the german Mercks’ chemists Anton Kollisch was the first to synthesize 3‚4 metilendioxide-N-methamphetamin (also known as MDMA. Merck was the first company to get the patent to MDMA numbered 274 350 in 1914. Firstly‚ the competitive advantages that Merck possesses is economies
Premium Management Stock market Strategic management
Jim Mesplie MBA 519 – Competitive Strategy Case Analysis #4 FACTS Beginning as a small scale manufacturer of chemical in the United States‚ Merck Research Labs (MRL) became the top notch research institution in the pharmaceutical industry by World War II. By attracting the top talent in chemistry‚ biology‚ and pharmacology‚ MRL emerged as the leader in human pharmaceuticals with the release of highly necessary drugs to treat infections‚ and tuberculosis. MRL focused their strengths on three
Premium Generic drug Pharmacology Pharmaceutical industry
Analysis on Merck: Conflict and change Assessment: Merck is one of the biggest pharmaceutical companies in the world today. Although encountered with success‚ it still faces many problems today while trying to be the market leader competing against its competition. While being research and development driven company‚ Merck now has to go beyond R&D to stay competitive in the pharmaceutical industry. The main issue that seems to come
Premium Pharmaceutical industry Pharmacology
Executive Summary Merck & Company has been presented with an opportunity to invest $30 million for the purchasing rights of an obesity and high cholesterol lowering drug‚ KL-798 from Kappa Labs. Based on the expected probabilities of success through each product-development phase for this new drug‚ as well as the costs involved‚ the net present value of the project is -$1.16 million and is therefore recommended that Merck passes on the investment. Sensitivity analysis also show that adjusting
Premium Clinical trial Net present value Investment